Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Pulmonary Dysfunction in Childhood Cancer Patients
Sponsor: University Children's Hospital Basel
Summary
This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.
Official title: Prospective Multicentre Cohort Study of Early Pulmonary Dysfunction in Childhood Cancer Patients (SWISS-Pearl Study)
Key Details
Gender
All
Age Range
4 Years - 22 Years
Study Type
OBSERVATIONAL
Enrollment
140
Start Date
2021-06-01
Completion Date
2051-06
Last Updated
2025-03-26
Healthy Volunteers
No
Conditions
Interventions
Lung function measurements
All lung function tests are non-invasive and last about 60 minutes per child: * Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged. * Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits.
Breath Analysis
Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
Magnetic resonance imaging (MRI)
Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
Standardized interview to assess respiratory symptoms
Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT
Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
Collection of genetic samples
Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
Locations (5)
University Children's Hospital Basel (UKBB)
Basel, Switzerland
Universitätsklinik für Kinderheilkunde
Bern, Switzerland
Geneva University Hospital
Geneva, Switzerland
Centre hospitalier universitaire vaudois Lausanne
Lausanne, Switzerland
Universitäts-Kinderspital Zürich
Zurich, Switzerland